UC-Berkeley Rekindles U.S. Patent Dispute with the Broad Institute over CRISPRAllbiopro2019-08-02T09:16:19+09:008월 2nd, 2019|
Cities and Regions Invest in the Life Sciences to Bolster Economic GrowthAllbiopro2019-08-02T09:15:18+09:008월 2nd, 2019|
Novartis’ Kisqali Effective in Postmenopausal Women with Breast CancerAllbiopro2019-08-02T09:14:46+09:008월 2nd, 2019|
Adaptimmune’s R&D Boss Departing, Leaving Executive Holes to FillAllbiopro2019-08-02T09:14:16+09:008월 2nd, 2019|
Study: Patients’ Immune Reactions to Checkpoint Inhibitors May Reflect Better 5-Year Survival RatesAllbiopro2019-08-02T09:13:48+09:008월 2nd, 2019|
Boston’s Vida Ventures Snags $600 Million for New Life Science FundAllbiopro2019-08-02T09:13:14+09:008월 2nd, 2019|
Merck’s spending big to support Gardasil, and the HPV vaccine keeps pumping alongAllbiopro2019-08-02T09:12:11+09:008월 2nd, 2019|
After Fresenius deal collapse, Akorn inks $74M settlement with investors over data integrity woesAllbiopro2019-08-02T09:11:38+09:008월 2nd, 2019|
Wiping its slate ahead of BMS buy, Celgene to pay $117M in Revlimid antitrust settlementsAllbiopro2019-08-02T09:11:05+09:008월 2nd, 2019|
Pfizer’s GSK consumer deal is closed, and generics go next. Will its cash flow recover?Allbiopro2019-08-02T09:10:33+09:008월 2nd, 2019|
Belldegrun’s Vida raises $600M biotech investment fundAllbiopro2019-08-02T09:09:58+09:008월 2nd, 2019|
Amicus shares early look at Batten disease gene therapyAllbiopro2019-08-02T09:09:27+09:008월 2nd, 2019|
Adaptimmune R&D chief leaves at dawn of critical trialAllbiopro2019-08-02T09:08:55+09:008월 2nd, 2019|
Chipscreen upsizes IPO as investors flock to China’s STAR MarketAllbiopro2019-08-02T09:08:22+09:008월 2nd, 2019|
EuroBiotech Report—R&D execs leave Adaptimmune and Zealand, Wellington fund, Gilead and WoodfordAllbiopro2019-08-02T09:07:49+09:008월 2nd, 2019|
